Juelg | Ragon Institute of Mass General, MIT, and Harvard

Boris D. Juelg

Boris D. Juelg, MD, PhD

Principal Investigator

Group Leader

Ragon Institute of Mass General, MIT, and Harvard

Infectious Diseases Division

MGH

Center for Virology and Vaccine Research

BIDMC

Contact

857-268-7088

600 Main street, Room 256

Infectious Diseases Clinical Research Unit

Center for Virology and Vaccine Research

Natural infections informing immunotherapies

Research Overview

The Juelg lab aims to link preclinical and clinical studies to identify and test the most promising immunological strategies to prevent and treat infections. The lab is specifically interested in evaluating passive and active immunization approaches using broadly neutralizing antibodies and novel vaccine candidates.

About

Dr. Juelg received an MD and PhD from Christian Albrecht University in Kiel, Germany. He completed a postdoctoral research fellowship with Dr. Bruce Walker before undergoing internal medicine training at MGH and a fellowship in infectious diseases through the combined program at MGH and Brigham and Women’s Hospital.

Selected Publications

Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodies. Immunity.

Nziza N, Jung W, Mendu M, Chen T, Julg B, Graham B, Ramilo O, Mejias A, Alter G

Immunity. 2024 Jul 9;57(7):1681-1695.e4.

Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy.

Julg B, Stephenson KE, Tomaka F, Walsh SR, Sabrina Tan C, Lavreys L, Sarnecki M, Ansel JL, Kanjilal DG, Jaegle K, Speidel T, Nkolola JP, Borducchi EN, Braams E, Pattacini L, Burgess E, Ilan S, Bartsch Y, Yanosick KE, Seaman MS, Stieh DJ, van Duijn J, Willems W, Robb ML, Michael NL, Walker BD, Pau MG, Schuitemaker H, Barouch DH.

NPJ Vaccines. 2024 May 23;9(1):89.

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.

Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, Chege W, Yacovone M, Hanscom B, Heptinstall J, Seaton KE, Zhang L, Miner MD, Eaton A, Weiner JA, Mayer K, Kalams S, Stephenson K, Julg B, Caskey M, Nussenzweig M, Gama L, Barouch DH, Ackerman ME, Tomaras GD, Huang Y, Montefiori D; HVTN 130/HPTN 089 Study Team.

Lancet HIV. 2023 Oct;10(10):e653-e662.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, Ansel J, Kanjilal D, Nkolola J, Walker-Sperling VEK, Ophel J, Yanosick K, Borducchi EN, Maxfield L, Abbink P, Peter L, Yates NL, Wesley MS, Hassell T, Gelderblom HC, deCamp A, Mayer BT, Sato A, Gerber MW, Giorgi EE, Gama L, Koup RA, Mascola JR, Monczor A, Lupo S, Rolle CP, Arduino R, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH.

Nat Med. 2022 Jun;28(6):1288-1296

Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs.

Wang C, Schlub TE, Yu WH, Tan CS, Stefic K, Gianella S, Smith DM, Lauffenburger DA, Chaillon A, Julg B.

Clin Infect Dis. 2022 Oct 12;75(8):1342-1350.

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.

Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH.

Nat Med. 2021 Oct;27(10):1718-1724.

Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-COV-2

Ang Gao, Zhilin Chen, Assaf Amitai, Julia Doelger, Vamsee Mallajosyula, Emily Sundquist, Florencia Pereyra Segal, Mary Carrington, Mark M Davis, Hendrik Streeck, Arup K. Chakraborty, Boris Julg.

iScience. 2021

Viral rebound kinetics correlate with distinct HIV antibody features

Bartsch YC, Loos C, Rossignol E, Fajnzylber JM, Yuan D, Avihingsanon A, Ubolyam S, Jupimai T, Hirschel B, Ananworanich J, Lauffenburger DA, Li JZ, Alter G, Julg B.

mBio. 2021 Mar 9;12(2):e00170-21